Individuals aren’t the only ones making New Year’s Resolutions. Three biotech companies want to start out the new year with a new start—as publicly traded companies.
With the end of the 2017 first quarter on the near horizon, speculation is increasing on merger-and-acquisition activity in biopharma. StreetInsider listed eight biopharma companies it thinks are likely targets. Let’s take a look.
Biotech stocks have taken a beating in 2016 and even the “Trump Bump” for pharma stocks was short-lived. But, a new year brings new hope for investors. A Motley Fool analyst thinks he has three stocks that could “shine” next year.